<DOC>
	<DOCNO>NCT02993276</DOCNO>
	<brief_summary>This post-market surveillance study conduct provide post market surveillance information regard long-term performance ease use Polyganics nerve cap device ( NEUROCAP® ) reduction development peripheral symptomatic end-neuroma .</brief_summary>
	<brief_title>Evaluation NEUROCAP® In Treatment Symptomatic Neuroma</brief_title>
	<detailed_description>1 . Device description NEUROCAP® , bioresorbable nerve cap device base upon NEUROLAC® nerve guide , indicate protect peripheral nerve end separate nerve surround environment reduce development symptomatic neuroma . NEUROCAP® compose biocompatible , bioresorbable copolyester compose NEUROLAC® nerve guide , Poly ( 68/32 [ 15/85 D/L ] Lactide-Ԑ-Caprolactone ) ( PLCL ) . 2 . Objective This post-market surveillance study conduct provide post market surveillance information regard long-term performance ease use Polyganics nerve cap device ( NEUROCAP® ) reduction development peripheral symptomatic end-neuroma . 3 . Study design This post-market surveillance study consist cohort study provide post market surveillance information regard long-term performance ease use NEUROCAP® reduction development peripheral symptomatic end-neuroma upper low extremity . Sub analyse perform regard demographic medical background .</detailed_description>
	<mesh_term>Neuroma</mesh_term>
	<criteria>1 . Subjects able provide write informed consent prior participate clinical investigation . 2 . Subjects able comply followup requirement . 3 . Subjects ≥ 18 year old . 4 . Subjects diagnosis peripheral symptomatic ( end ) neuroma upper limb . 5 . Subjects positive Tinel 's sign . 6 . Symptomatic neuroma confirm pain relief follow 10min ± 2min nerve block Xylocaine ( Lidocaine ) Pain relief define minimally 50 % reduction VAS questionnaire score . 7 . Subjects indicate surgery treat symptomatic neuroma . 1 . Subjects complete informed consent . 2 . Subjects willing follow postsurgery protocol ( e.g . avoid pressure implant zone immobilization ) . 3 . Subjects unable comply followup requirement and/or life expectancy le 24 month . 4 . Subjects congenital neuropathy . 5 . Insufficient amount soft tissue cover investigational device , assess surgeon . Use device joint advise . 6 . Subjects historical radiotherapy area ( end ) neuroma . 7 . Subjects know allergy anesthetic agent bioresorbable copolyester Poly ( 68/32 [ 15/85 D/L ] LactideεCaprolactone ) ( PLCL ) . 8 . Proximal nerve end &gt; 8mm . 9 . Pregnancy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>